2018 American Transplant Congress
An Individualized Strategy Using Virus and Immune-Based Markers to Prevent Cytomegalovirus Disease after Face Transplantation
Introduction: There is limited data on CMV prevention after face transplantation. We report an individualized approach using prophylaxis followed by surveillance and preemptive therapy guided…2018 American Transplant Congress
Recovery of Wild-Type Genotype after Documented Ganciclovir-Resistance in Transplant Recipients with Recurrent CMV Viremia
Purpose: Ganciclovir-resistant cytomegalovirus (GR-CMV) is serious complication after transplantation. Recurrence after primary GR-CMV infection is common, with literature defined rates of approximately 20-30%. It is…2018 American Transplant Congress
Multidisciplinary Approach to Prevention of Cytomegalovirus (CMV) Complications in Kidney and Liver Transplant Recipients
Background: CMV infection can be prevented in most SOT recipients providing that a prevention protocol is followed. We discovered that our center's protocol, which includes…2018 American Transplant Congress
Cytomegalovirus Prophylaxis Following Alemtuzumab Induction in High Risk Renal Transplant Recipients Experiencing Delayed Graft Function
University of Maryland, Baltimore.
Purpose: There is limited data to support the use of valganciclovir in patients on dialysis. This study assessed the efficacy of valganciclovir 450 mg twice…2018 American Transplant Congress
Evaluation of the Use of Oral Valganciclovir for the Treatment of Cytomegalovirus Infections in Pediatric Intestinal Transplant Recipients: A Single Center Review
Purpose: To evaluate the safety and efficacy of oral valganciclovir in treating cytomegalovirus (CMV) infections in pediatric intestinal transplant recipients (pITR).Methods: This retrospective review included…2017 American Transplant Congress
Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.
Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…2017 American Transplant Congress
Ganciclovir Resistant Cytomegalovirus Infection in Abdominal Tansplant Recipients.
University of Wisconsin Hospital and Clinics, Madison
Purpose: Single center evaluation of ganciclovir-resistant cytomegalovirus (GR-CMV) incidence, treatment and outcomes.Methods: Review of adult abdominal transplant (aSOT) recipients from 1/1/1995-12/31/2015 with documented GR-CMV infection.Results:…2016 American Transplant Congress
Subclinical Cytomegalovirus Viraemia in Renal Transplant Recipients.
Background: Studies suggest low-level cytomegalovirus (CMV) viraemia, detected with sensitive molecular assays, may lead to poorer graft outcomes following renal transplantation.Aims: Investigate the incidence, outcomes,…2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…2016 American Transplant Congress
Clinical Predictors of Progression and Clearance of Low Level CMV Viremia in Solid Organ Transplant Recipients.
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.
Background: Low level CMV viremia is common, and may either progress to higher viral loads that require therapy, or may spontaneously resolve. The clinical predictors…
American Transplant Congress abstracts